Pursuant to section 23(1) of the Medicines Act 1981, the Minister of Health hereby provisionally consents to the sale, supply or use in New Zealand of the new medicines set out in the Schedule hereto:
Schedule
Product: | Pomalidomide Sandoz |
Active Ingredient: | Pomalidomide 1mg |
Dosage Form: | Capsule |
New Zealand Sponsor: | Sandoz New Zealand Limited |
Manufacturer: | Synthon Hispania SL, Barcelona, Spain |
Note: This consent is given subject to the following conditions:
|
|
Note: This consent is valid for two years from the date of publication of this notice. | |
Product: | Pomalidomide Sandoz |
Active Ingredient: | Pomalidomide 2mg |
Dosage Form: | Capsule |
New Zealand Sponsor: | Sandoz New Zealand Limited |
Manufacturer: | Synthon Hispania SL, Barcelona, Spain |
Note: This consent is given subject to the following conditions:
|
|
Note: This consent is valid for two years from the date of publication of this notice. | |
Product: | Pomalidomide Sandoz |
Active Ingredient: | Pomalidomide 3mg |
Dosage Form: | Capsule |
New Zealand Sponsor: | Sandoz New Zealand Limited |
Manufacturer: | Synthon Hispania SL, Barcelona, Spain |
Note: This consent is given subject to the following conditions:
|
|
Note: This consent is valid for two years from the date of publication of this notice. | |
Product: | Pomalidomide Sandoz |
Active Ingredient: | Pomalidomide 4mg |
Dosage Form: | Capsule |
New Zealand Sponsor: | Sandoz New Zealand Limited |
Manufacturer: | Synthon Hispania SL, Barcelona, Spain |
Note: This consent is given subject to the following conditions:
|
|
Note: This consent is valid for two years from the date of publication of this notice. |
Dated this 8th day of December 2023.
CHRIS JAMES, Group Manager, Medsafe, Ministry of Health (pursuant to delegation given by the Minister of Health on 11 September 2013).